Investing

Micron Technology Stock News

Micron Technology Stock NewsMicron Technology, Inc. (NASDAQ: MU)

Micron is scheduled to release its earnings report for the second fiscal quarter of 2015 tomorrow. While there’s a bit of a debate on the boards about whether or not the report will be positive, by the growth we’re seeing in the stock today, it seems as though the majority consensus is that we are going to see good things.

Looking For Clues In Last Quarter’s Results

When I attempt to predict whether or not we’ll see a positive earnings report, I tend to look to the last quarter for a gauge of recent earnings activity from the company. In this particular case, results for the first fiscal quarter of 2015 were mixed. Overall, the news was good as the company posted surprise earnings, but there was some bad news in the fact that total revenue was a bit of a miss.

MU Has Made Some Big Moves This Quarter

One thing that we have to take into account is the fact that Micron Technology has made a few big moves this quarter. One of the biggest being their collaboration with Intel; which allows them to reach a much broader audience. This should surely prove to be profitable on the earnings report.

The Negative Side Of The Coin

On another note, some analysts have a negative view of what we are going to see in tomorrow’s earnings report. Their argument is simple. They believe that the company is struggling is growth, and they made that fact apparent by missing earnings last quarter.

What We Should See From MU Earnings

I think the earnings report will be positive overall. While last quarter’s results did show a revenue miss, the company surprised investors by passing out profits. Also, with the Intel partnership, I’m definitely expecting to see the growth problem under control.

How MU Stock Is Moving Today

Micron Technology stock has great upward momentum today. Currently (12:20), it’s trading at $26.98 per share after a gain of 1.12%; and should continue to rise.

What Do You Think?

What do you think we’re going to see from the MU earnings report? Let us know in the comments below!

Genetic Technologies Stock News

Genetic Technologies Stock NewsGenetic Technologies Limited (ADR) (NASDAQ: GENE)

Genetic Technologies has had a rough time in the market lately. Recently, the company went on a very successful fund raising spree. However, to raise the funds, they had to issue new shares; ultimately causing share dilution and leading to a weeks long downtrend.

What We Saw From Genetic Technologies Yesterday

Yesterday, it seemed as though investors decided that dilution was no longer an issue and started pumping money into the stock. By mid day, it was up more than 20% and would keep climbing. In the end, GENE climbed to $4.94 per share by the closing bell!

Investor Excitement Is Keeping The Momentum Alive

As we see in several cases, after posting impressive gains, a breakout starts to become visible in the charts as more and more investors and day traders decide they’d like to get in on the action. Today, Genetic Technologies stock is definitely in breakout mode. Currently (11:54), GENE is trading at $5.43 per share after a gain of 9.92% so far today.

What We Can Expect From GENE Throughout The Rest Of The Week

It seems clear that Genetic Technologies stock will end in the green today; however, I do think that we may be reaching the too much too fast type of growth. So, I’ll be watching the charts for parabolic patterns telling me that the stock has maxed out. While I do think that the stock will end the week in the green, at some point either tomorrow or Thursday, we’ll most likely see a correction in the stock as we tend to see after any small-cap biotech breakout. Nonetheless, this is a great company and in the long run, I’m expecting to see great things!

What Do You Think?

Where do you think Genetic Technologies stock is headed and why? Let us know in the comments below!

BlackBerry Stock News

BlackBerry Stock NewsBlackBerry Ltd (NASDAQ: BBRY)

BlackBerry stock has had a rough time in the market lately. After a critical downgrade from Goldman Sachs, investors seem to have lost faith in the stock, causing it to plummet. However, on Friday, the company shocked the world by producing net gains in a quarter that analysts thought they would lose $10 to $18 million. So, there was a slight improvement in the stock’s value Friday.

Then, yesterday more questions came out about the company. While investors were happy to see that they were able to create a profit, there was a bright red flag in the earnings report. Total revenue missed analyst expectations by more than $100 million. As a result, the value of the stock slipped yesterday.

What’s Happening With BBRY Today?

BlackBerry started the trading day on a bit of a down note, but the stock has recovered a bit since then. Currently (11:28), the stock is trading at $8.85 per share after a gain of 0.57% so far.

Where Will BlackBerry Go Long Term?

Although I’ve caught a bit of flack when it comes to my views on BBRY stock, this is one that I’m particularly bullish on. Now, don’t get me wrong, short term price volatility is going to be an issue for at least a few months; so, this isn’t one to buy into for short-term gains. However, it’s also important to remember that BBRY is moving its software business up the ladder fast, and in the world of the Internet of Things, BlackBerry hardware will play a key role in the long run. That being said, I think we’re going to see some great long term gains from BBRY stock.

What Do You Think?

Where do you think BBRY stock is headed and why? Let us know in the comments below!

Biotech news today

Biotech news todayRxi Pharmaceuticals Corp (NASDAQ: RXII)

Rxi Pharmaceuticals last week on March 23, 2015 presented at the 73rd Annual Academy of Dermatology in which the company reported  positive progress on clinical trial updates for its dermatology programs. The clinical trial with RXI-109-1301 phase 2a enrolled patients to be tested for hypertrophic scars on the abdomen only. In addition the company initiated a second Phase 2a hypertrophic scar study RXI-109-1402 that enrolled patients with scars in various locations on the body. Finally the company updated the Keloid trial RXI-109-1401 in which patients have their keloid removed in surgery and then receive an injection with RXI-109 to determine the recurrence effect of the keloid.

With respect to RXI-109-1301– hypertrophic scar study —  the company reported already that initiating treatment with RXI-109 2-weeks post scar revision surgery displayed greater results than when initiating RXI-109 at the time of surgery. A blinded panel concluded that RXI-109 showed a greater effect over placebo at both the 1-month and 3-month intervals when RXI-109 was given to patients 2-weeks post surgery as opposed to immediately at surgery. With these finding the company then initiated RXI-109-1402 mentioned above in which the company will have to adjust dosing levels and provide more doses over the course of the scar proliferation phase — phase where scar continues to grow one year out. Study RXI-109-1301 patients are completely enrolled and further data will be evaluated at month 9. Study RXI-109-1402 is more than 50% complete on enrollment but patients continue to enter the study.

In respect to the keloid study RXI-109-1401 the company reported that the panel identified a greater recurrence of the keloid with the placebo treatment. This means that RXI-109 was doing a better job keeping keloids low on CTGF compared to placebo. The panel which was compromised of practicing dermatologists, plastic surgeons, and actual investigators in the study unanimously recommended that Rxi initiate a new trial with higher dosing and more doses over the course of the proliferation phase so that it can tackle the aggressive growth of keloids. This is good news because if the panel had concluded that placebo was performing better than RXI-109 then the panel wouldn’t have recommended for the company to continue with another keloid trial.

Rxi had a busy week because it had also announced that it had made a licensing deal with a privately held pharmaceutical company known as MirImmune LLC. The Company, MirImmune, will be developing cell-based cancer immunotherapy treatments using Rxi’s proprietary sd-rxRNA technology platform — self delivering siRNA molecules– using checkpoint inhibitors. Under the terms of the deal MirImmune will be responsible for all clinical costs relating to the development, manufacturing, regulatory and commercialization efforts of these cancer therapies. Rxi on the other hand will be receiving an annual licensing fee, clinical milestone payments, sublicensing income, and single digit royalties. If the trials produce positive results Rxi then has the option to buy a double-digit equity stake in MirImmune.

Merck & Co., Inc. (NYSE: MRK)

On March 24, 2015 Merck announced that it had obtained positive results in its phase 3 clinical trial program in patients with melanoma. The trial was stopped early because the results far exceeded those of the current standard of care therapy data. Melanoma is a type of skin cancer where the skin becomes damaged by DNA rearrangement. It is the most deadliest form of skin cancer and there are more than 120,000 people in the U.S. that were diagnosed with Melanoma in 2014. If the cancer is caught early then it can easily be treated but if it has spread to other parts of the body then it can be fatal.

The phase 3 trial known as KEYNOTE-006 recruited up to 834 patients who were split up into three different dosing groups in the study. The drug used by Merck to treat these patients with Melanoma is known as KEYTRUDA — pembrolizumab. The patients recruited in the study were stage 3 or stage 4 in Melanoma — advanced stages of cancer — who only had received one prior standard of care therapy. KEYTRUDA is a monoclonal antibody that is responsible for blocking PD-1 — programmed cell death receptor 1 — and its ligands PD-1/PD-2. The best current standard of care therapy for Melanoma at the moment comes from Bristol-Myers Squibb (BMY) which has developed a drug known as Yervoy — ipilimumab. Each one of the patients were classified into a certain dose group. Patients either took KEYTRUDA 10 mg/kg every 3-weeks, KEYTRUDA 10 mg/kg every 2-weeks, or 4 cycles of ipilimumab 3 mg/kg every 3-weeks.

The trial met the primary endpoints of two key objectives. The first primary endpoint tested progression-free survival and the other primary endpoint tested overall-survival. Merck met on both primary endpoints and in addition fared much better than the patients that took the placebo treatment ipilimumab. The full trial results though won’t be shown until some time in April where the company will present updated data at the 2015 American Association of Cancer Research Annual Meeting — AACR — which will take place in Philadelphia. In addition to positive clinical results in the phase 3 KEYNOTE-006 study the company reported that it would initiate a $10 billion dollar share repurchase program. Although the share repurchase program won’t take place all at once. Instead Merck will be buying its shares on the open market at various time intervals. Whether this will help the share price climb higher remains to be seen but the company is on the right track with its cancer drug which may prove to be successful in many other types of cancers as well.

Conatus Pharmaceuticals Inc (NASDAQ: CNAT)

Shares of Conatus Pharmaceuticals surged as high as 18% on March 26, 2015 after the company reported positive phase 2 results in its trial that treated patients with NASH which stands for non-alcoholic steatohepatitis. As the name suggests these patients have liver disease but not due too excessive use of alcohol. The phase 2 trial recruited just about 38 patients who either took 25 mg of emricasan or a placebo compound; both over a 28 day period. The primary endpoint of the trial was a measurement of NASH known as alanine amino transferase — ALT. These ALT are enzymes that are found on the cells of the liver and kidney. The company analyzed the results and determined that the p-value of p < .05 was statistically significant over placebo.

The liver needs ALT enzymes to survive but the problem is that NASH patients have too much of these enzymes which leads to a build up of fatty deposits in the liver. Looking more specifically  into these results the ermicasan 25 mg group achieved an ALT enzyme reduction of 39% from baseline measurement while the placebo group only achieved a 14% ALT enzyme reduction. Even looking at the results in terms of percentages emricasan, Conatus’ drug, achieved more than double the reduction of ALT enzymes.

Why are these results exciting? Well for starters NASH drug development is a huge space because of the enormous market potential. Many analysts estimate that a NASH drug on the open market could possibly produce between $35 to $40 billion dollars by 2025. In addition the company has met with the FDA for early approval for emricasan based on a surrogate endpoint. A surrogate endpoint is a clinical efficacy measurement that the FDA establishes for a company to be able to file for early approval — Accelerated Approval.

Back in 2014 Intercept Pharmaceuticals (ICPT) reported that it stopped its phase 2 NASH trial early because the trial had met the primary endpoint in an interim analysis using its drug obeticholic acid — OCA. The Data safety monitoring committee has decided to stop the FLINT trial because of the positive data seen in the study. The patients saw a statistically significant improvement in histological data, obtaining a p-value of p < 0.0024 intent to treat, and in addition showed no worsening of fibrosis – scarring of the liver — as compared to placebo. Conatus may now be up to par with Intercept Pharmaceuticals but which one will win out in the end is up for grabs. Although considering the large market size for NASH we are pretty sure there will be plenty of room for both players in the space. In addition there are many other biotechnology companies who are working on NASH as well so we will just have to wait and see how the competition in this space persuades the market in the end.

Disclosure: Long Rxi Pharmaceuticals (RXII) , no position in other stocks mentioned

Image Credit

Facebook Stock News

Facebook Stock NewsFacebook Inc (NASDAQ: FB)

Facebook stock had a rough week in the market last week. They weren’t the only stock however. As a matter of fact, the Dow Jones Industrial Average, S&P 500, and NASDAQ all closed the week in the red. Nonetheless, I think we’re going to see something completely different from Facebook this week.

We’ve Seen Quite A Bit Of Good News From Facebook Recently

One of the reasons I think we’re going to see a bit of a recovery this week is the fact that the news moves the market. Recently, we’ve been seeing quite a bit of good news. With stories talking about why Oculus will drive FB higher, analyst price target increases, and more, it only makes sense that Facebook stock will climb in value.

The Market Should Recover As A Whole

Last week, we saw a Spring sell off, mixed with concerns over the United States’ economic strength. While those concerns may not be gone entirely, it seems as though people have stopped talking about durable goods orders, the Federal Reserve increasing interest rates, and other economic hits we’ve been seeing in media lately. Instead, the major media outlets seem to be focusing on much more positive news. As I mentioned above, since the news moves the market, I think this is a sign of good things to come this week.

What We Saw From FB Today

FB started the day off falling; reaching $82.50 per share by 11:55. However, from there, we’ve started to see a recovery in the price of shares. Currently (2:17), FB is flirting with yesterday’s close; trading at $83.29 per share after a loss of 0.01%.

What Do You Think?

Do you think FB will make a recovery this week? Why or why not? Let us know in the comments below!

Genetic Technologies Stock News

Genetic Technologies Stock NewsGenetic Technologies Limited (ADR) (NASDAQ: GENE)

When it comes to Genetic Technologies in the market recently, the key word has been dilution. Recently, the company raised millions of dollars; issuing new shares to do so. As a result, dilution hit the price of the stock hard; causing it to plummet from $9.82 per share on February 18th to a close of $3.70 per share on Friday.

It Seems As Though Dilution Is No Longer An Issue

While share dilution did bring the stock to incredible lows over the past month and a half, it seems as though the issue is behind us as investors started to jump in with heavy volume today. As a result, the company’s stock skyrocketed. By 9:30, heavy trade volume brought the company’s stock price to $4.03 per share; and that would prove to be just the beginning. Currently (1:02), GENE is trading at $4.54 per share after a gain of 22.70% so far today.

What We Can Expect From GENE Moving Forward

Back in February, when this drop began, I weighed in with my opinion of the company; stating that I believe we will see a bit of a decline from share dilution, followed by strong gains in the long run. I’ve got to admit that the decline we saw was much heavier than what I expected. Nonetheless, I still have faith in the fact that Genetic Technologies is a great company with great things to offer the biotech space! With that being said, I’m still expecting long term growth out of GENE.

What Do You Think?

Where do you think Genetic Technologies stock is headed? Why? Let us know in the comments below!

Twitter Stock News

Twitter Stock NewsTwitter Inc (NYSE: TWTR)

Twitter had a rough week in the market last week along with most other tech and biotech stocks. As the spring sell off started, in conjunction with the fact that investors have started to become concerned about increasing interest rates; US stocks seemed to fall down the drain. Unfortunately, Twitter is falling again today, but I think we’re going to see a bounce back before the end of the week. There are a few reasons for this…

  • Economic Concerns Aren’t Big News This Week – While we haven’t seen a major change in the economy over the weekend; no one seems to be talking about interest rates, poor durable goods orders, or anything else that would be viewed as negative on the economic side. All focus in the market seems to be on corporate growth.
  • Twitter Is Making Moves For Growth – Recently we’ve heard about larger mobile ads and other moves the company has been making to position itself for growth.
  • The Stock Is Down Right Cheap – Because of the declines we’ve seen lately, Twitter stock is trading at a low. Since our goal as investors is to buy low and sell high, this presents a perfect opportunity.

 

What We’ve Seen From TWTR Today

Today, Twitter stock fell throughout most of the day, but seems to have started to stabilize. Currently (12:48), TWTR is trading at $49.04 per share after a loss of 1.94% so far today.

What We Can Expect From Twitter This Week

As mentioned above, I’m expecting TWTR to end the week in the green. Sure, we’re off to a bit of a rough start; but there are plenty of great reasons to invest in this company. As economic concerns die down, we will most likely see TWTR start to rise.

What Do You Think?

Where do you think TWTR is headed and why? Let us know in the comments below!

ZIOP XON Partnership

ZIOP XON PartnershipZIOPHARM Oncology Inc. (NASDAQ: ZIOP)

Intrexon (NYSE: XON)

ZIOPHARM Oncology and Intrexon stocks gained heavily in early morning trading due to high trade volume. The companies announced that they would be working together to strengthen their oncology programs. Moving forward, the team will focus on novel chimeric antigen receptor T-cell, also known as CAR-T products in Germany. By moving ZIOP products into Germany through
Intrexon’s collaboration, both companies will share the upfront payment, royalties, and milestones equally.

What We’re Seeing In The Market Today

ZIOPHARM Oncology – ZIOPHARM Oncology stock saw sharp gains in early morning trading; climbing to $13.20 per share on heavy volume by 9:30. However, the early morning momentum has leveled off; leaving ZIOP with small gains so far today. Currently (12:24), the stock is trading at $11.70 per share after a gain of 2.27%.

Intrexon – Intrexon seems to have followed the same path as ZIOPHARM. By 9:30 heavy trade volume brought the price to $48.60 per share. After stabilizing, XON is currently (12:26) trading at $46.51 per share after a gain of 8.16% so far today.

What We Can Expect From ZIOP and XON Moving Forward

Both of these companies are incredibly strong players with room for growth. Their partnership in CAR-T products only makes them stronger. With that said, I think we can expect great long term growth out of both of them.

What Do You Think?

Where do you think ZIOP and XON are headed? Why? Let us know in the comments below!

Image Credit

BlackBerry Stock News

BlackBerry LogoBlackBerry Ltd (NASDAQ: BBRY)

BlackBerry stocks are falling hard today as investors start to raise questions about the company’s earnings report release on Friday. While the company was able to produce gains, and analysts expected losses, the total revenue generated was more than $100 million less than expected. Today, the tone has changed quite a bit from EPS conversations to revenue stabilization.

BBRY In The Market Today

As mentioned above, BlackBerry is having a hard time in the market today. Currently (11:53), the stock is trading at $8.82 per share after a fall of 6.77% so far.

What We Can Expect Moving Forward

While I understand why investors are starting to raise questions about revenue growth and the ability to stabilize, I’m still a bull on BBRY. That’s because the company is growing its software business, and while revenue was a big miss, they were able to generate profits. There’s no doubt that BlackBerry has quite a bit of work ahead of them; but I firmly believe that they are moving in the right direction.

What Do You Think?

Where do you think BBRY is headed and why? Let us know in the comments below!

MannKind Stock News

MannKind Stock NewsMannKind Corporation (NASDAQ: MNKD)

There’s been quite a bit of debate about MannKind stock recently. The bottom line is that when it comes to MannKind stock, investors either love it or hate it. However, I think that’s all going to change relatively soon. As investors, our goal is to buy low and sell high; MNKD is giving us the opportunity to do just that. Over the next several months (3-6) I think that the investors that hate it, will come to love it. Here’s why…

Why Investors Turned Their Backs On MannKind Corporation In The First Place

If you look at MannKind over the last 3 months, you see what seems to be a flat line with a mountain in the middle. On January 20th; MNKD started to rise greatly as the diabetes medication Afrezza became available. However, just a few weeks later, an analyst at Goldman Sachs downgraded the stock due to what he considered to be a weak launch of the inhaled insulin. Personally, I believe that the downgrade was unfounded; a belief among many that is leading to quite the debate…

Those Who Hate It – Those who hate it use the analyst’s pitch about the stock being a poor option because of Afrezza as ammo. They say that if Afrezza really was a great thing for the diabetic community, it would have taken off like a rocket.

Those Who Love It – Those who love it say the analyst spoke way too soon. We argue that the new insulin only had weeks on the market to show sales and that this type of thing could take years; but will still be incredibly lucrative.

It Seems As Though Some Are Already Starting To Change Their Minds

While it may be a few years before we see the full potential of Afrezza in action, you don’t have to look to far to see that some who may have doubted the stock are starting to see it in a new light. As physicians start to give their feedback on Afrezza, analysts are starting to increase their price target for MNKD stock.

What We Can Expect From MNKD

I think we’re going to see quite a bit of growth in the near and long-term outlook for the stock. While it’s important to remember that you will see heavy price volatility in any small cap biotech stock, there’s also plenty of reasons for this one to start to explode yet again. So, we’re going to see small dips, but over the next month, and in the long term, we should see a positive trend prevail.

What Do You Think?

Where do you think MannKind stock is heading and why? Let us know in the comments below.

Thought Leader Discussions

Gevo, Inc. GEVO Stock News

0 4557
Gevo, Inc. (NASDAQ: GEVO) Before we get into this interview, I'd like to extend a special thanks to my friend Joey who both set up the...